Edap TMS SA released its first quarter 2025 financial results, reporting a total worldwide revenue of EUR 13.6 million (USD 14.3 million), marking a 9.1% decrease compared to EUR 14.9 million (USD 16.1 million) in the same period of 2024. The gross profit for the first quarter was EUR 5.7 million (USD 6.0 million), down from EUR 6.4 million (USD 6.9 million) in 2024, with a gross profit margin of 42.0%, slightly lower than the 42.8% recorded in the previous year. The operating loss increased to EUR 6.0 million (USD 6.3 million) from EUR 4.8 million (USD 5.2 million) in the first quarter of 2024. The net loss for the quarter was EUR 7.1 million (USD 7.5 million), compared to a net loss of EUR 4.5 million (USD 4.9 million) in the previous year. The company highlighted significant progress in its operations, including a record number of Focal One® Robotic HIFU System placements for a first quarter period. Additionally, Edap TMS received CE Mark designation for the Focal One system for the treatment of deep infiltrating endometriosis. It also launched the new Focal One i Robotic HIFU System and successfully performed the world's first remote transcontinental Focal One Robotic HIFU procedure. Looking forward, Edap TMS is maintaining its 2025 financial guidance, anticipating a year-over-year revenue growth of 16 to 25% in its core HIFU business, and expecting revenue declines of 20 to 25% in its non-core businesses, including ESWL and Distribution. As of March 31, 2025, the company's cash and cash equivalents stood at EUR 22.8 million (USD 24.6 million), down from EUR 29.8 million (USD 30.9 million) as of December 31, 2024.